 | |
| Company type | Public limited company |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1993 |
| Defunct | 1999 |
| Fate | Merged with Astra AB |
| Successor | AstraZeneca |
| Headquarters | London, UK |
| Products | Pharmaceutical products |
Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom. It was formed in June 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries into a separate company listed on the London Stock Exchange.[1]
In 1999, Zeneca and the Sweden-based pharmaceutical company Astra AB merged to form AstraZeneca plc.[2][3]
Zeneca's largest therapeutic area was oncology, in which its key products included Casodex, Nolvadex and Zoladex.[4] Other key products included heart drug Tenormin.[5]
- ^ "Timetable for Zeneca demerger spelled out". The Independent. 26 February 1993. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
- ^ "Zeneca and Astra merge to form drug giant". BBC News. 9 December 1998. Retrieved 5 July 2011.
- ^ "Corporate Profile: The arranged marriage". The Independent. 24 February 1999. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
- ^ "Pound batters drug giant". BBC News. 6 August 1998. Retrieved 5 July 2011.
- ^ "Zeneca profits up 42% in first year after demerger: Volume and price growth, but conditions remain tough". The Independent. 4 March 1994. Archived from the original on 7 May 2022. Retrieved 5 July 2011.